Peringatan Keamanan

There is no information regarding the acute toxicity (LD₅₀) of vonicog alfa. No symptoms of overdose with von Willebrand factor have been reported. Thromboembolic events may occur in case of a major overdose.^L51274

Vonicog alfa

DB12872

biotech approved investigational

Deskripsi

Vonicog alfa is a recombinant human von Willebrand factor (rVWF) produced from Chinese hamster ovary cells.^A264444 Used to treat von Willebrand Disease (vWD), it mimics the biological actions of endogenous VWF,^L51274 which is a critical plasma glycoprotein involved in platelet adhesion and aggregation.^A264389 Vonicog alfa works to reduce bleeding events and bleeding times in patients with vWD, who have deficiencies in VWF.^A264389

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler

Obat Target Gen Interaksi Enzim Transporter Carrier

Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

1. Pendahuluan & Konsep

Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).

2. Sumber Data (Validasi)

Data Obat: Diekstraksi dari elemen drugbank-id dan name pada skema XML DrugBank.
Target Protein: Diambil dari elemen targets/target yang memuat polipeptida sasaran.
Genetik: Disinkronisasi dari sub-elemen gene-name dan varian snp-effects.
Genetik: Jumlah titik node dibatasi pada maksimal 10 (Slice=10) interaksi untuk menghindari tumpukan data.

3. Algoritma Visualisasi

Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.

4. Legenda Visual

Obat Utama (Pusat Analisis)

Target Protein (Mekanisme)

Gen (Faktor Genetik)

Metode ini mendukung analisis Precision Medicine dan evaluasi risiko Drug-Drug Interaction (DDI).

Profil Farmakokinetik

Waktu Paruh (Half-Life) In Study 071001, the mean half-life was 22.6 hours and 19.1 hours following an infusion of 50 IU/kg von Willebrand factor ristocetin cofactor (VWF:RCo), respectively.[L51274]

Volume Distribusi -

Klirens (Clearance) In Study 071001, the mean clearance was 0.02 dL/kg/hours and 0.03 dL/kg/hours following an infusion of 50 IU/kg von Willebrand factor ristocetin cofactor (VWF:RCo), respectively.[L51274]

Absorpsi

Study 071001 enrolled patients with VWD: in this study, the mean incremental recovery at C_max was 1.9 (IU/dL)/(IU VWF:RCo/kg) and 2.0 (IU/dL)/(IU VWF:RCo/kg) after an infusion of 50 IU/kg von Willebrand factor ristocetin cofactor (VWF:RCo), respectively.^L51274 The mean AUC_0-inf was 2105.4 (h*IU/dL) and 2939.0 (h*IU/dL).^L51274

Metabolisme

The endogenous regulator of the vWF is ADAMTS13. The interaction between these two proteins results in the proteolysis of vWF. This proteolysis occurs primarily in the cleavage site at the domain A2, which is a target domain for ADAMTS13.^A32290

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

0 Data

Tidak ada data.

Target Protein

Coagulation factor VIII F8

Collagen alpha-1(I) chain COL1A1

Referensi & Sumber

Artikel (PubMed)

PMID: 31902122
Tran T, Arnall J, Moore DC, Ward L, Palkimas S, Man L: Vonicog alfa for the management of von Willebrand disease: a comprehensive review and single-center experience. J Thromb Thrombolysis. 2020 Apr;49(3):431-440. doi: 10.1007/s11239-019-02018-1.
PMID: 35439298
Leebeek FWG, Peyvandi F, Escobar M, Tiede A, Castaman G, Wang M, Wynn T, Baptista J, Wang Y, Zhang J, Mellgard B, Ozen G: Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood. 2022 Jul 14;140(2):89-98. doi: 10.1182/blood.2021014810.
PMID: 28276537
Singal M, Kouides PA: Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease. Drugs Today (Barc). 2016 Dec;52(12):653-664. doi: 10.1358/dot.2016.52.12.2570978.
PMID: 36405429
Gritsch H, Schrenk G, Weinhappl N, Mellgard B, Ewenstein B, Turecek PL: Structure and Function of Recombinant versus Plasma-Derived von Willebrand Factor and Impact on Multimer Pharmacokinetics in von Willebrand Disease. J Blood Med. 2022 Nov 14;13:649-662. doi: 10.2147/JBM.S377126. eCollection 2022.

Link

EMA Approved Drug Products: Veyvondi (vonicog alfa) Intravenous Injection

Contoh Produk & Brand

Produk: 4 • International brands: 0

Produk

Veyvondi

Injection, powder, for solution • 650 IU • Intravenous • EU • Approved
Veyvondi

Injection, powder, for solution • 1300 IU • Intravenous • EU • Approved
Vonvendi

Powder, for solution • 650 unit / vial • Intravenous • Canada • Approved
Vonvendi

Powder, for solution • 1300 unit / vial • Intravenous • Canada • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.